Organisation paid for research Program year 2025 Source: CMS Open Payments

Community Hospital

Neither a doctor nor a teaching hospital

Research payments

$206,748

42 payments

Through program year 2025, Community Hospital is reported as receiving $206,748 in research payments, across 42 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $556 2
2024 Research $29,328 4
2023 Research $33,382 13
2022 Research $14,440 3
2021 Research $22,872 6
2020 Research $14,397 4
2019 Research $91,775 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $108,396 21 payments
  2. Philips Electronics North America Corporation $38,033 6 payments
  3. AngioDynamics, Inc. $17,378 3 payments
  4. Genentech, Inc. $17,112 4 payments
  5. Atricure, Inc. $15,357 2 payments
  6. Radius Health, Inc. $6,263 1 payment
  7. Boston Scientific Corporation $4,121 4 payments
  8. E.R. Squibb & Sons, L.L.C. $89 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects KEYNOTE-189 $54,747 6 payments
  2. A Randomized Double-Blind, Phase III Study of Platinum+Pemtrexed Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189) $34,693 2 payments
  3. Tenecteplase in Stroke Patients Between 4 5 and 24 Hours $17,112 4 payments
  4. Distal Evaluation of Functional Performance With Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting (DEFINE GPS) $16,170 1 payment
  5. Igt-Pvi $15,650 2 payments
  6. Left Atrial Appendage Ligation With the Lariat Suture Delivery System As Adjunctive Therapy to Pulmonary Vein Isolation for Persistent Or Longstanding Persisten Atrial Fibrillation $15,357 2 payments
  7. A Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects KEYNOTE-189 $15,106 4 payments
  8. Apex $13,678 2 payments
  9. A Randomized, Multicenter, Phase 2 Study of Elacestrant (Rad1901) Versus Investigators Choice of Fulvestrant Or Aromatase Inhibitor Therapy for the Treatment of Postmenopausal Women With Er+/Her2- Breast Cancer $6,263 1 payment
  10. Define GPS $6,100 2 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $17,378 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record